Curis Analyst Price Targets - Benzinga

SPY—QQQ749.55−0.00%BTC/USD85,279.99+0.63%DIA511.70+0.12%GLD380.52+0.10%TLT77.53+0.06%

Curis Inc

CRISNASDAQ

Trade with Public

Trade with Public

$0.8034

-0.0273-3.29%

Last update: Oct 2, 5:33 PM

$0.8600

0.02933.53%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Curis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Curis (CRIS).

Price Target Range — 9 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$306Upside to Avg. PT+35452.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$43
Jul 24, 2026	HC Wainwright & Co.	Sara Nik	PT Raise	Buy	$17→$43
Mar 20, 2026	HC Wainwright & Co.	Sara Nik	Maintained	Buy	$17
May 19, 2025	HC Wainwright & Co.	Joseph Pantginis	Assumes	Buy	$17
Mar 31, 2025	HC Wainwright & Co.	Edward White	PT Cut	Buy	$20→$16
Dec 10, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$20
Nov 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$20
Nov 1, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$26→$20
Sep 27, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$26
Aug 1, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$26
May 15, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$26
May 15, 2024	Truist Securities	Robyn Karnauskas	Maintained	Buy	$26
May 15, 2024	Cantor Fitzgerald	Li Watsek	Maintained	Overweight	—
May 8, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$26
Feb 9, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$51→$26
Nov 17, 2023	Truist Securities	Robyn Karnauskas	Initiate	Buy	$26

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $43 price target.

Benzinga Newsdesk

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.

Vandana Singh

PRO
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43

HC Wainwright & Co. analyst Sara Nik maintains Curis (NASDAQ:CRIS) with a Buy and raises the price target from $17 to $43.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $17 Price Target

HC Wainwright & Co. analyst Sara Nik reiterates Curis (NASDAQ:CRIS) with a Buy and maintains $17 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Curis at Buy, Announces Price Target of $17

HC Wainwright & Co. analyst Joseph Pantginis assumes Curis (NASDAQ:CRIS) with a Buy rating and announces Price Target of $17.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $16

HC Wainwright & Co. analyst Edward White maintains Curis (NASDAQ:CRIS) with a Buy and lowers the price target from $20 to $16.

Benzinga Newsdesk